[1] Khedagi AM, Bello NA. Hypertensive disorders of pregnancy[J]. Cardiol Clin,2021,39(1):77-90. [2] Sinkey RG,Battarbee AN,Bello NA,et al. Prevention, diagnosis, and management of hypertensive disorders of pregnancy: a comparison of international guidelines[J]. Curr Hypertens Rep,2020,22(9):66-68. [3] Garovic VD,Dechend R,Easterling T,et al. Hypertension in pregnancy: diagnosis, blood pressure goals, and pharmacotherapy: a scientific statement from the American Heart Association[J]. Hypertension,2022,79(2):21-41. [4] 刘佳,张方芳,杨照静. PAPP-A、NT值及β-HCG检测在胎儿染色体遗传疾病中诊断效能研究[J]. 实用预防医学,2021,28(2):199-202. [5] Huang T, Bedford HM, Rashid S, et al. Modified multiple marker aneuploidy screening as a primary screening test for preeclampsia[J]. BMC Pregnancy Childb,2022,22(1):190192. [6] Stepan H, Hund M, Andraczek T. Combining biomarkers to predict pregnancy complications and redefine preeclampsia: the angiogenic-placental syndrome[J]. Hypertension,2020,75(4):918-926. [7] Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice[J]. Hypertension,2018,72(1):24-43. [8] 乐杰.妇产科学[M].第6版.北京:人民卫生出版社,2005:97-105. [9] 王昊,胡蓉. 妊娠期高血压疾病与子代心血管疾病关系研究进展[J]. 现代妇产科进展,2022,31(1):72-74. [10] 仓决卓玛,次巴卓玛,郭娟,等. 2010—2017年西藏山南市孕产妇死亡率趋势及影响因素分析[J]. 实用预防医学,2019,26(10):1219-1223. [11] Suresh SC, Rana S. Real-world use of biomarkers in management of hypertension during pregnancy: adjunct to clinical care[J]. Hypertension,2021,77(2):472-474. [12] Magee LA,von Dadelszen P. Treatment for mild chronic hypertension during pregnancy[J]. N Engl J Med,2022,387(7):664. [13] Johnson S, Liu B, Kalafat E, et al. Maternal and perinatal outcomes of white coat hypertension during pregnancy: a systematic review and meta-analysis[J]. Hypertension,2020,76(1):157-166. [14] Garovic VD,White WM,Vaughan L,et al. Incidence and long-term outcomes of hypertensive disorders of pregnancy[J]. J Am Coll Cardiol,2020,75(18):2323-2334. [15] 程华英,胡娅萍,郑璇,等. 妊娠期高血压疾病孕妇血清AGEs、TGF-β1、PAPP-A及RBP4变化及临床意义[J]. 分子诊断与治疗杂志,2022,14(4):631-634,638. [16] 王静,张曙萱. PAPP-A、sFlt-1、TTR在妊娠期高血压疾病诊断中的价值[J]. 中国妇幼健康研究,2021,32(3):350-354. [17] 刘佩琳,马丽丽,高万里. 血清PLGF、PAPP-A、β-HCG与妊娠期高血压疾病的相关性及预测不良妊娠结局价值[J]. 中国计划生育学杂志,2022,30(5):1154-1158. [18] 马姣荣,刘成云. 妊娠相关血浆蛋白-A、超敏C反应蛋白与妊娠期高血压疾病的关系[J]. 海南医学,2019,30(15):1959-1961. [19] 李红妮,郭亮,席翠萍. 血清MMP-9、β-hCG联合检测对胎膜早破合并宫内支原体感染的预测价值[J]. 医学临床研究,2022,39(6):843-846. [20] 马晓梅,杨美霞. 高龄孕妇血清AFP、F-β-hCG及uE3水平与不良妊娠结局的相关性[J]. 中国计划生育学杂志,2021,29(8):1749-1752. [21] 曾成碧,颜璐,雷娇,等. 孕妇血清游离β-hCG及uE2水平对妊娠期并发症及妊娠结局影响[J]. 中国计划生育学杂志,2021,29(8):1714-1717. [22] 周娟,韩克. 妊娠期高血压患者血清sLOX-1与β-hCG及妊娠结局的相关性[J]. 中国计划生育学杂志,2018,26(10):961-964. [23] 徐慧,柯凤梅,吴小莉,等. 中性粒细胞淋巴细胞比值与妊娠期高血压疾病严重程度及妊娠不良结局的相关性[J]. 中国计划生育和妇产科,2021,13(4):29-32. [24] 郭秋云,李静,冯春华. 血清LRRFIP1、sFlt-1/PLGF诊断高龄孕妇并发妊娠期高血压疾病及预后价值[J]. 中国计划生育学杂志,2020,28(7):1087-1090,1094. [25] 陈益明,卢莎,顾琳媛,等. 中孕期血清可溶性血管内皮生长因子受体1、胎盘生长因子水平及其比值筛查妊娠期高血压疾病的效率[J]. 中国卫生检验杂志,2020,30(4):434-438.
2023, Vol. 30 
